Press "Enter" to skip to content

Fecal Transplants Better Option To Treat Fatal Bacterial Infection: Study

Fecal transplants are better compared to antibiotics when saving lives and thwarting fatal bloodstream infections in individuals dismayed by persistent and pernicious bacteria, reported a recent study. For long, the method, also dubbed fecal microbiota transplantation (FMT), is been utilized for treating bacterial infections resulted from Clostridium difficile (C. difficile), that do not react to antibiotics. FMT entails transplanting processed stool from a hale and hearty person into the sick patient’s gut.

At the Fondazione Policlinico Gemelli IRCCS in Rome, Dr. Gianluca Ianiro, the Lead Author of the study and a FMT & microbiome specialist, stated, “Prior to this research, we recognized that FMT was more efficient compared to antibiotics in treating recurring C. difficile infection, however, now we recognize that it is also more efficient in thwarting C. difficile -associated complications.” The study of Ianiro discovered that FMT in comparison with antibiotics boosted survival of patients by over 30%, slashed the duration of hospital stays to half, and decreased the chances of sepsis, or bloodstream infection, by fourfold.

Ianiro believes there are numerous factors elucidating the lower chances of bloodstream infection in individuals who underwent FMT. They comprise a shorter hospital stay that is identified to decrease the possibility of bloodstream infections; treating the actual infection that decreases the chances of bacteria leaking into the bloodstream from the intestines; and the likelihood that FMT may result in fewer multidrug-resistant bacteria occurring in the patients’ guts.

On the other end, RedHill Biopharma Ltd recently stated that its 3-drug combination treatment for curing Helicobacter pylori bacterial infections had been sanctioned by the US FDA (Food and Drug Administration), taking its stakes up by 25%. Talicia, the drug, is an oral capsule entailing 2 antibiotics, rifabutin and amoxicillin, in addition to an ordinary therapy for heartburn, omeprazole. The treatment is anticipated to be introduced in next year’s first quarter.

Stacy Howard
Stacy Howard Subscriber
CONTRIBUTING AUTHOR At Industry Updates 24

Stacy Howard has studied Biomedical Engineering and is a certified medical coder. She looks after the health domain at our organization. Stacy believes in honest communication, nurturing relationships and having a kind of fun along the way. After work hours, she is busy with helping a non-profit organization with underprivileged children. Presently, she is focusing on raising awareness about oral health in children.

Be First to Comment

Leave a Reply

Your email address will not be published. Required fields are marked *